Please login to the form below

Not currently logged in

LabCorp to acquire Covance for $5.6bn

Combines diagnostics expertise with contract research
Covance boxes

Diagnostics firm Laboratory Corporation of America Holdings (LabCorp) has added drug development to its business with the acquisition of contract research organisation Covance.

The deal, valued at $5.6bn, creates one of the world's leading healthcare diagnostic companies, combining LabCorp's expertise in medical testing and the full-service drug development of Covance, which includes market access and nutritional businesses.

The combined company will leverage technologies that improve patient recruitment for clinical trials, enhance efficiency in the conduct of clinical trials and deliver data faster to drug sponsors, physicians and patients.

LabCorp chairman and CEO David P King and LabCorp chief financial officer Glenn Eisenberg will serve in the same positions for the combined company. Covance chairman and CEO Joe Herring will lead LabCorp's Covance division and report directly to King.

King commented: “By joining our highly compatible and complementary capabilities, the combined company will be an industry leader in both the laboratory and CRO spaces, characterised by global scale, enhanced offerings, new efficiencies, broader and deeper customer relationships, and a differentiated business model.”

Herring added: “We are thrilled to join forces with another industry leader through a transaction that delivers to our shareholders substantial immediate cash value along with a meaningful stake in a combined company with exciting growth opportunities.”

The combined company will remain at LabCorp's headquarters in Burlington, North Carolina, while the Covance division headquarters will still be based in Princeton, New Jersey.

The transaction is expected to close in the first quarter of 2015.

Article by
Kirstie Pickering

5th November 2014

From: Research



Related Hub content

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....